Primary extranodal lymphoma of the glands. Literature review and options for best practice in 2019

dc.contributor.authorBelkacemi, Yazid
dc.contributor.authorSio, Terence T.
dc.contributor.authorColson-Durand, Laurianne
dc.contributor.authorOnal, Cem
dc.contributor.authorVilla, Salvador
dc.contributor.authorAnacak, Yavuz
dc.contributor.authorKrengli, Marco
dc.contributor.authorThariat, Juliette
dc.contributor.authorUgurluer, Gamze
dc.contributor.authorMiller, Robert C.
dc.contributor.authorMirimanoff, Rene-Olivier
dc.contributor.authorOzsahin, Mahmut
dc.contributor.authorTo, Nhu Hanh
dc.date.accessioned2023-02-21T12:41:38Z
dc.date.available2023-02-21T12:41:38Z
dc.date.issued2019-01-01
dc.description.abstractPrimary extranodal non-Hodgkin's lymphomas (EN-NHL) are a heterogeneous group of malignancies that involve numerous entities with significant difference in terms of tumor site locations, prognostic factors, biology expression, and therapeutic options. In the literature, many EN-NHL types were reported from limited series which only allowed narrow views for elucidating prognostic factors and defining the role of loco-regional therapies in the era of new systemic and biologically targeted therapies. The Rare Cancer Network (RCN), an international multidisciplinary consortium, has published a number of reports on several EN-NHL sites which included many gland locations. In this review, we will focus on the recent literature for a selected number of EN-NHL types in both exocrine and endocrine gland locations. We aim to provide renewed and clear messages for the best practice in 2019 for diagnosis, histopathology, treatments, and also their prognostic implications. We believe that better understanding of molecular and genetic characteristics of these particular diseases is crucial for an appropriate management in the era of personalized treatment developments.
dc.description.issueMAR
dc.description.pages8-19
dc.description.volume135
dc.identifier.doi10.1016/j.critrevonc.2019.01.005
dc.identifier.urihttps://hdl.handle.net/11443/2737
dc.identifier.urihttp://dx.doi.org/10.1016/j.critrevonc.2019.01.005
dc.identifier.wosWOS:000461262800002
dc.publisherELSEVIER SCIENCE INC
dc.relation.ispartofCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
dc.subjectLymphoma
dc.subjectExtranodal non-Hodgkinlymphoma
dc.subjectGlands
dc.subjectRadiation therapy
dc.subjectClinical practice
dc.subjectRare cancer
dc.subjectRituximab
dc.titlePrimary extranodal lymphoma of the glands. Literature review and options for best practice in 2019
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
1-s2.0-S104084281730570X-main.pdf
Size:
395.23 KB
Format:
Adobe Portable Document Format

Collections